Psilocybin Psychotherapy with Acceptance and Commitment Therapy: A Potential Treatment for Social Anxiety Disorder

Individuals diagnosed with social anxiety disorder are in need of a more effective therapeutic intervention. Due to the nature of SAD, individuals tend to not seek care for their treatment, leading to the continuation of avoidance behaviors that significantly impact their daily existence. Psilocybin psychotherapy has the potential to lead to significant changes in the personality structure of individuals as well as reducing anxious responses to their environment in a relatively short period of time. Acceptance and commitment therapy can serve as the ideal therapeutic backing to psilocybin as it emphasizes mindfulness and psychological flexibility, both of which aid in the therapeutic mechanisms of psilocybin. This paper serves as a review of existing literature surrounding ACT and psilocybin, centering around the potential benefits of a psilocybin psychotherapy program with ACT as a therapeutic base for individuals with SAD. A description of a potential psilocybin psychotherapy program is included

Brain size and brain/intracranial volume ratio in major mental illness

<p>Abstract</p> <p>Background</p> <p>This paper summarizes the findings of a long term study addressing the question of how several brain volume measure are related to three major mental illnesses in a Colorado subject group. It reports results obtained from a large N, collected and analyzed by the same laboratory over a multiyear period, with visually guided MRI segmentation being the primary initial analytic tool.</p> <p>Methods</p> <p>Intracerebral volume (ICV), total brain volume (TBV), ventricular volume (VV), ventricular/brain ratio (VBR), and TBV/ICV ratios were calculated from a total of 224 subject MRIs collected over a period of 13 years. Subject groups included controls (C, N = 89), and patients with schizophrenia (SZ, N = 58), bipolar disorder (BD, N = 51), and schizoaffective disorder (SAD, N = 26).</p> <p>Results</p> <p>ICV, TBV, and VV measures compared favorably with values obtained by other research groups, but in this study did not differ significantly between groups. TBV/ICV ratios were significantly decreased, and VBR increased, in the SZ and BD groups compared to the C group. The SAD group did not differ from C on any measure.</p> <p>Conclusions</p> <p>In this study TBV/ICV and VBR ratios separated SZ and BD patients from controls. Of interest however, SAD patients did not differ from controls on these measures. The findings suggest that the gross measure of TBV may not reliably differ in the major mental illnesses to a degree useful in diagnosis, likely due to the intrinsic variability of the measures in question; the differences in VBR appear more robust across studies. Differences in some of these findings compared to earlier reports from several laboratories finding significant differences between groups in VV and TBV may relate to phenomenological drift, differences in analytic techniques, and possibly the "file drawer problem".</p

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Psilocybin Psychotherapy with Acceptance and Commitment Therapy: A Potential Treatment for Social Anxiety Disorder

Individuals diagnosed with social anxiety disorder (SAD) require effective therapeutic interventions. Due to the nature of SAD, individuals tend to not seek care for their treatment, leading to the continuation of avoidance behaviors that significantly impact their daily existence. Psilocybin psychotherapy has the potential to lead to significant changes in the personality structure of individuals as well as reducing anxious responses to their environment in a relatively short period of time. Acceptance and commitment therapy (ACT) can serve as the ideal therapeutic backing to psilocybin as it emphasizes mindfulness and psychological flexibility, both of which aid in the therapeutic mechanisms of psilocybin. This paper reviews existing literature surrounding ACT and psilocybin, centering around the potential benefits of a psilocybin psychotherapy program with ACT as a therapeutic base for individuals with SAD. A description of a potential psilocybin psychotherapy program is included